Currently, three biomarkers are FDA-approved to guide anti-PD-1/PD-L1 therapies: (1) PD-L1 expression [124,125]; (2) mismatch repair deficiency [126] and (3) tumor mutational burden [127,128]. Here, PDCD1 is linked to neoplasm.